Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Invited Commentary Invited Commentary Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse Theodore P. Braun, MD, PhD; Brian J. Druker, MD More than 20 years ago, the first patients were enrolled in a median follow-up of 42 months, approximately 60% of pa- the phase 1 trial of imatinib for treatment of chronic myeloid tients remained in TFR after treatment discontinuation. leukemia (CML). Inhibiting the kinase activity of the BCR- Patient-reported outcomes were assessed 12 months ABL1 fusion protein, the driving molecular abnormality of after discontinuation and showed that patients in TFR had this disease, has rendered clinically meaningful improvements in fatigue, depression, this once deadly leukemia a gastrointestinal upset, sleep, and pain. While not unsurpris- Related article manageable condition. For ing, these findings are consequential. Although there is no patients with CML, a good disease outcome with nearly nor- doubt that the currently available ABL TKIs cause many mal lifespan is expected, but treatment adverse effects objectively assessed adverse effects, such as fluid retention, remain a significant issue. While adverse effect profiles pleural effusions, and
JAMA Oncology – American Medical Association
Published: Jan 12, 2021
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera